Biogen Inc (NASDAQ:BIIB)

U.S. Markets are not yet open, but BIIB is being traded in the pre-market session. Pre-Market quote »
401.71
Delayed Data
As of Apr 24
 -28.57 / -6.64%
Today’s Change
275.39
Today|||52-Week Range
480.18
+18.34%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$94.2B

Company Description

Biogen, Inc. is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. Its products include AVONEX, TYSABRI, FAMPYRA, RITUXAN and FUMADERM. AVONEX product is indicated for the treatment of patients with relapsing forms of MS to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. TYSABRI product is indicated for the treatment of relapsing forms of MS as a monotherapy to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. This product is also used for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation. FAMPYRA product is indicated for the improvement of walking ability in adult patients with MS who have walking disability. FUMADERM product is only approved in Germany and is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom topical therapy is ineffective. RITUXAN product is indicated for treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP or other anthracycline-based chemotherapy regimens; and for previously untreated follicular. The company was founded on November 12, 2003 and is headquartered in Cambridge, MA.

Contact Information

Biogen, Inc.
225 Binney Street
Cambridge Massachusetts 02142
P:(781) 464-2000
Investor Relations:

Employees

Shareholders

Mutual fund holders57.17%
Other institutional35.78%
Individual stakeholders1.15%

Top Executives

George A. ScangosChief Executive Officer & Director
Paul J. ClancyChief Financial Officer & Executive Vice President
Raymond PawlickiChief Information Officer & Senior Vice President
Douglas E. WilliamsExecutive Vice President-Research & Development
Spyridon Artavanis-TsakonasChief Scientific Officer & Senior Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account